Harrow Health stock
HROWNASDAQHarrow Health, Inc., HealthcareISIN US4158581094
39Score 39 out of 100, Weak
Price and trend
43 / 100
Price history
−26% in one yearThe chart shows daily closes over 19 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 25% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 49).
The price is 48% below its 52-week high. Largest decline in 19 years: 99% (October 2007 to June 2011).
Chart figures for advanced users
- SMA 50$30.94
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$37.57
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)49
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.04
- The lowest closing price of the last twelve months.
- Resistance$54.80
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Harrow Health, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $1.06B, is number 66 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $272.3M (up 36.4% year on year) and a loss of $5.14M.
- For fiscal 2026, analysts expect on average revenue of $349.65M (up 28.4%) and adjusted earnings per share of −$0.31.
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 565 of 714 in Healthcare, median 53.
- Our model puts fair value at $104.20, with the price 72% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 41% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 70
Weaknesses
- High debtDebt 10.43 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 28
- DilutionShare count up 42% since 2020.Capital allocation 20
- Interest barely coveredOperating profit covers interest only 0.9 times.Stability 28
Its standout strengths are valuation and growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 39.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $69.46 and expensive above $208.39 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $84.38, at 7.8% it would be $134.11.
Possible value trap: looks cheap, but score below 50, high risk, weak balance sheet.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 21.3% on the twelve months before. Revenue turned from negative at the start of the period to positive ($272.3M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 75%, operating 14%, net −2%. Last 12 months: net −9%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 1 Mar 2027in 109 days
- Last reported
- 9 Nov 2026EPS reported $0.25 (expected $0.19)above expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 321.2% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$0.31−321.2%
- Revenue
- $349.65M−0.2%
- Earnings per share
- $1.86−14.7%
- Revenue
- $520.71M−2.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −3.3%2026 guidance reiterated: revenue of $350 million to $365 million and adjusted EBITDA of $80 million to $100 million, despite a lighter first half.
“Turning now to our outlook, we are reiterating full year guidance of $350 million to $365 million in revenue and $80 million to $100 million in adjusted EBITDA. Based on first half revenue of approximately $115 million, our guidance implies second half revenue of approximately $235 million to $250 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
4 insiders bought on the open market between 14 May 2026 and 18 May 2026, $468,720 in total. One insider sold, $450,000 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Harrow Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Cronos GroupCRON $1.26B61
- BioGaiaBIOG-B.ST $1.25B75
- Amphastar PharmaceuticalsAMPH $1.22B76
- VetoquinolVETO.PA $1.13B77
- PharmanutraPHN.MI $906.68M62
- Ironwood PharmaceuticalsIRWD $806.23M71
- Collegium PharmaceuticalCOLL $770.98M52
- EvotecEVT.DE $624.43M32
ETFs that hold Harrow Health
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.06% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.06% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.03% | 0.30% | €4.22B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.03% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.19B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2023)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.